Stock Analysis on Net

IQVIA Holdings Inc. (NYSE:IQV)

This company has been moved to the archive! The financial data has not been updated since November 1, 2023.

Analysis of Short-term (Operating) Activity Ratios
Quarterly Data

Microsoft Excel

Short-term Activity Ratios (Summary)

IQVIA Holdings Inc., short-term (operating) activity ratios (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Turnover Ratios
Receivables turnover 4.60 4.68 4.73 4.94 5.42 5.28 5.36 5.44 5.81 5.68 5.09 4.71 4.54 4.61 4.24 4.29 4.33 4.46 4.28 4.35
Working capital turnover 51.93 16.90 21.35 21.65 29.97 30.16 61.26 25.97 22.17 21.19 30.62
Average No. Days
Average receivable collection period 79 78 77 74 67 69 68 67 63 64 72 77 80 79 86 85 84 82 85 84

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

Short-term activity ratio Description The company
Receivables turnover An activity ratio equal to revenue divided by receivables. IQVIA Holdings Inc. receivables turnover ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.

Short-term activity ratio Description The company
Average receivable collection period An activity ratio equal to the number of days in the period divided by receivables turnover. IQVIA Holdings Inc. number of days of receivables outstanding deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.

Receivables Turnover

IQVIA Holdings Inc., receivables turnover calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in millions)
Revenues 3,736 3,728 3,652 3,739 3,562 3,541 3,568 3,636 3,391 3,438 3,409 3,298 2,786 2,521 2,754 2,895 2,769 2,740 2,684 2,688 2,594 2,567 2,563
Trade accounts receivable and unbilled services, net 3,227 3,139 3,063 2,917 2,640 2,679 2,619 2,551 2,330 2,276 2,361 2,410 2,414 2,371 2,634 2,582 2,514 2,401 2,461 2,394 2,298 2,172 2,250
Short-term Activity Ratio
Receivables turnover1 4.60 4.68 4.73 4.94 5.42 5.28 5.36 5.44 5.81 5.68 5.09 4.71 4.54 4.61 4.24 4.29 4.33 4.46 4.28 4.35
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc. 4.83 4.88 4.95 5.16 5.38 5.10 5.29 5.63 5.94 5.42 5.24 5.19 4.83 4.34 5.35 6.13
Amgen Inc. 4.17 4.34 4.34 4.46 4.60 4.62 4.81 4.96 5.11 5.39 5.41 5.36 5.81 4.31 4.55 5.47
Danaher Corp. 6.15 6.64 6.89 6.40 7.09 6.81 6.87 6.36 6.69 6.51 6.28 5.51 5.83 5.59 5.25 5.61
Eli Lilly & Co. 3.93 3.93 3.68 4.14 4.35 4.57 4.64 4.24 4.69 4.58 4.56 4.18 4.75 4.75 4.52 4.91
Gilead Sciences Inc. 5.68 6.43 6.43 5.65 6.16 6.60 7.18 6.01 5.95 6.34 6.43 4.98 5.83 6.84 5.73 6.18
Johnson & Johnson 5.91 5.36 5.65 5.88 6.04 5.92 6.08 6.14 6.13 6.00 5.64 6.08 5.55 5.50 5.56 5.67
Merck & Co. Inc. 5.71 5.29 5.56 6.27 6.22 5.93 5.49 5.28 5.56 6.00 5.65 6.11 5.62 6.23 5.88 6.91
Moderna Inc. 4.68 43.53 12.88 13.31 7.61 8.25 6.89 5.57 3.48 3.03 0.60 0.14 0.00 0.00 0.00 0.00
Pfizer Inc. 6.25 7.66 7.57 9.16 6.21 6.68 6.99 7.08 5.81 5.23 4.70 5.28 4.29 4.96 4.93 5.93
Regeneron Pharmaceuticals Inc. 2.35 2.47 2.42 2.28 2.47 2.76 3.41 2.66 2.48 1.77 2.20 2.07 2.04 2.84 2.72 2.94
Thermo Fisher Scientific Inc. 5.19 5.43 5.53 5.53 5.76 5.53 5.21 4.92 7.03 6.99 6.46 5.61 5.49 5.86 5.69 5.87

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
Receivables turnover = (RevenuesQ3 2023 + RevenuesQ2 2023 + RevenuesQ1 2023 + RevenuesQ4 2022) ÷ Trade accounts receivable and unbilled services, net
= (3,736 + 3,728 + 3,652 + 3,739) ÷ 3,227 = 4.60

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Receivables turnover An activity ratio equal to revenue divided by receivables. IQVIA Holdings Inc. receivables turnover ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.

Working Capital Turnover

IQVIA Holdings Inc., working capital turnover calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in millions)
Current assets 5,208 5,329 5,328 4,981 4,752 4,911 4,772 4,763 4,534 5,068 5,579 5,090 4,645 4,208 4,277 4,126 3,995 3,978 3,999 3,874 3,696 3,587 3,724
Less: Current liabilities 6,589 6,543 6,657 5,578 5,253 5,104 5,157 5,241 4,847 4,819 4,868 4,558 4,139 3,843 3,907 3,945 3,576 3,495 3,502 3,534 3,380 3,166 3,199
Working capital (1,381) (1,214) (1,329) (597) (501) (193) (385) (478) (313) 249 711 532 506 365 370 181 419 483 497 340 316 421 525
 
Revenues 3,736 3,728 3,652 3,739 3,562 3,541 3,568 3,636 3,391 3,438 3,409 3,298 2,786 2,521 2,754 2,895 2,769 2,740 2,684 2,688 2,594 2,567 2,563
Short-term Activity Ratio
Working capital turnover1 51.93 16.90 21.35 21.65 29.97 30.16 61.26 25.97 22.17 21.19 30.62
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc. 130.12 0.97 0.98
Amgen Inc. 0.81 0.84 0.82 3.82 2.52 3.67 4.34 3.37 2.55 5.35 2.84 2.55 1.87 1.87 3.27 3.96
Bristol-Myers Squibb Co. 10.47 5.53 5.55 8.30 5.75 4.92 6.24 3.95 4.43 4.24 4.25 3.72 2.77 3.09 2.38 2.28
Danaher Corp. 2.18 3.08 3.81 4.20 5.00 5.43 5.91 8.40 7.98 3.12 3.45 3.48 3.14 2.80 6.74 0.87
Eli Lilly & Co. 31.79 12.21 5.77 31.84 14.71 19.45 8.19 8.33 6.73 12.14 5.21 4.93 5.45 8.85 16.68 11.54
Gilead Sciences Inc. 6.74 84.15 9.14 8.42 8.56 6.87 6.68 8.54 7.25 7.09 7.06 5.30 1.07 1.55 1.24 1.08
Johnson & Johnson 9.37 14.06 23.02 4.88 5.02 5.57 5.95 5.97 5.93 7.26 9.44 4.32 8.83 7.85 8.81
Merck & Co. Inc. 6.69 8.86 5.63 5.16 5.58 6.39 6.09 7.62 6.51 6.97 84.97 109.83 7.67 6.59 17.87 8.90
Moderna Inc. 1.36 1.35 1.66 2.17 2.74 3.29 3.07 2.55 3.15 2.88 0.59 0.10 0.00 0.00 0.00 0.00
Pfizer Inc. 1.62 2.03 6.89 11.00 3.83 5.05 6.10 4.78 4.29 4.21 3.60 4.58 3.16 3.31 57.45
Regeneron Pharmaceuticals Inc. 0.87 0.92 0.90 0.96 1.09 1.14 1.46 1.59 1.35 1.29 1.35 1.20 1.22 1.92 1.21 1.41
Thermo Fisher Scientific Inc. 4.86 7.40 10.13 5.46 5.40 6.03 6.13 5.87 2.30 3.10 3.36 2.76 2.37 2.69 3.54 4.48

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
Working capital turnover = (RevenuesQ3 2023 + RevenuesQ2 2023 + RevenuesQ1 2023 + RevenuesQ4 2022) ÷ Working capital
= (3,736 + 3,728 + 3,652 + 3,739) ÷ -1,381 =

2 Click competitor name to see calculations.


Average Receivable Collection Period

IQVIA Holdings Inc., average receivable collection period calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data
Receivables turnover 4.60 4.68 4.73 4.94 5.42 5.28 5.36 5.44 5.81 5.68 5.09 4.71 4.54 4.61 4.24 4.29 4.33 4.46 4.28 4.35
Short-term Activity Ratio (no. days)
Average receivable collection period1 79 78 77 74 67 69 68 67 63 64 72 77 80 79 86 85 84 82 85 84
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc. 76 75 74 71 68 72 69 65 61 67 70 70 76 84 68 60
Amgen Inc. 88 84 84 82 79 79 76 74 71 68 67 68 63 85 80 67
Danaher Corp. 59 55 53 57 51 54 53 57 55 56 58 66 63 65 69 65
Eli Lilly & Co. 93 93 99 88 84 80 79 86 78 80 80 87 77 77 81 74
Gilead Sciences Inc. 64 57 57 65 59 55 51 61 61 58 57 73 63 53 64 59
Johnson & Johnson 62 68 65 62 60 62 60 59 60 61 65 60 66 66 66 64
Merck & Co. Inc. 64 69 66 58 59 62 66 69 66 61 65 60 65 59 62 53
Moderna Inc. 78 8 28 27 48 44 53 66 105 120 606 2,539
Pfizer Inc. 58 48 48 40 59 55 52 52 63 70 78 69 85 74 74 62
Regeneron Pharmaceuticals Inc. 156 148 151 160 148 132 107 137 147 206 166 177 179 128 134 124
Thermo Fisher Scientific Inc. 70 67 66 66 63 66 70 74 52 52 56 65 66 62 64 62

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 4.60 = 79

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Average receivable collection period An activity ratio equal to the number of days in the period divided by receivables turnover. IQVIA Holdings Inc. number of days of receivables outstanding deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.